MXPA03001160A - Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico. - Google Patents
Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico.Info
- Publication number
- MXPA03001160A MXPA03001160A MXPA03001160A MXPA03001160A MXPA03001160A MX PA03001160 A MXPA03001160 A MX PA03001160A MX PA03001160 A MXPA03001160 A MX PA03001160A MX PA03001160 A MXPA03001160 A MX PA03001160A MX PA03001160 A MXPA03001160 A MX PA03001160A
- Authority
- MX
- Mexico
- Prior art keywords
- retina
- optic nerve
- neurodegenerative disorders
- nerve head
- treating neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Se describe el uso de acidos 3-benzoilfenilaceticos y derivados, incluyendo nepafenaco, para tratar desordenes de retina neurodegenerativos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22513200P | 2000-08-14 | 2000-08-14 | |
PCT/US2001/025319 WO2002013805A2 (en) | 2000-08-14 | 2001-08-13 | Method of treating neurodegenerative disorders of the retina and optic nerve head |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03001160A true MXPA03001160A (es) | 2004-08-02 |
Family
ID=22843666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03001160A MXPA03001160A (es) | 2000-08-14 | 2001-08-13 | Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico. |
Country Status (17)
Country | Link |
---|---|
US (1) | US6638976B2 (es) |
EP (1) | EP1309322B1 (es) |
JP (1) | JP2004506010A (es) |
AR (1) | AR030346A1 (es) |
AT (1) | ATE330596T1 (es) |
AU (1) | AU8125801A (es) |
BR (1) | BR0113201A (es) |
CA (1) | CA2418059C (es) |
CY (1) | CY1106155T1 (es) |
DE (1) | DE60120990T2 (es) |
DK (1) | DK1309322T3 (es) |
ES (1) | ES2266229T3 (es) |
HK (1) | HK1057332A1 (es) |
MX (1) | MXPA03001160A (es) |
PT (1) | PT1309322E (es) |
TW (1) | TWI286933B (es) |
WO (1) | WO2002013805A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040132773A1 (en) * | 2001-08-13 | 2004-07-08 | Gamache Daniel A | Method of treating neurodgenerative disorders of the retina and optic nerve head |
JP2007500250A (ja) * | 2003-06-13 | 2007-01-11 | アルコン,インコーポレイテッド | 病的な眼の新脈管形成を処置するための非ステロイド性抗炎症剤の処方物 |
US20050009910A1 (en) * | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
TWI358290B (en) * | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
CN101175475B (zh) * | 2005-05-10 | 2010-04-14 | 爱尔康公司 | 包含活性成分、泊洛沙姆或美洛沙泊表面活性剂和二醇的混悬制剂、其用于生产治疗眼科病症的药物的用途 |
ATE412402T1 (de) * | 2005-05-10 | 2008-11-15 | Alcon Inc | Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen |
US9370444B2 (en) | 2010-10-12 | 2016-06-21 | Emmett T. Cunningham, JR. | Subconjunctival conformer device and uses thereof |
US8915877B2 (en) | 2010-10-12 | 2014-12-23 | Emmett T. Cunningham, JR. | Glaucoma drainage device and uses thereof |
RU2458656C1 (ru) * | 2011-06-17 | 2012-08-20 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Способ лечения оперированного незакрывшегося макулярного отверстия |
EP3013790A1 (en) | 2013-06-27 | 2016-05-04 | Mylan Laboratories Ltd. | Process for the preparation of nepafenac |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1226344A (es) | 1967-07-31 | 1971-03-24 | ||
SE400966B (sv) | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
US4313949A (en) | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
US4254146A (en) | 1979-10-18 | 1981-03-03 | A. H. Robins Company, Inc. | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters |
IL61945A (en) * | 1980-02-19 | 1984-09-30 | Robins Co Inc A H | 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them |
DE3026402A1 (de) * | 1980-07-11 | 1982-02-04 | Syntex Corp., Palo Alto, Calif. | Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen |
US4503073A (en) | 1981-01-07 | 1985-03-05 | A. H. Robins Company, Incorporated | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids |
IL64724A0 (en) * | 1981-02-17 | 1982-03-31 | Robins Co Inc A H | 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them |
US4454151A (en) | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
US4568695A (en) | 1983-12-07 | 1986-02-04 | A. H. Robins Company, Incorporated | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor |
US4851443A (en) | 1985-03-14 | 1989-07-25 | Smith Kline Dauelsberg, Gmbh | Carboxylic acid amides, compositions and medical use thereof |
DE3668450D1 (de) | 1985-03-14 | 1990-03-01 | Smithkline Dauelsberg | 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren. |
US4683242A (en) * | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
DK406686D0 (da) | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
CA1325382C (en) * | 1988-01-27 | 1993-12-21 | Takahiro Ogawa | Locally administrable therapeutic composition for inflammatory disease |
US5314909A (en) | 1993-03-17 | 1994-05-24 | Merck & Co., Inc. | Use of non-steroidal antiiflammatory agents in macular degeneration |
JP3396953B2 (ja) | 1994-05-10 | 2003-04-14 | 千寿製薬株式会社 | 網膜疾患予防・治療剤 |
US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
US5643943A (en) * | 1994-12-23 | 1997-07-01 | Alcon Laboratories, Inc. | Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis |
US5811446A (en) | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US6025353A (en) | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
IL144126A0 (en) | 1999-01-07 | 2002-05-23 | Univ Vanderbilt | A method of altering the specificity of cyclooxygenase-inhibiting compounds |
US6413965B1 (en) | 1999-06-30 | 2002-07-02 | Pfizer Inc. | Compositions and treatment for diabetic complications |
US6555540B1 (en) | 1999-06-30 | 2003-04-29 | Pfizer Inc | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
US6426341B1 (en) | 1999-06-30 | 2002-07-30 | Pfizer Inc. | Treatment for diabetic complications |
US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
-
2001
- 2001-08-10 AR ARP010103847A patent/AR030346A1/es not_active Application Discontinuation
- 2001-08-13 JP JP2002518951A patent/JP2004506010A/ja active Pending
- 2001-08-13 EP EP01959734A patent/EP1309322B1/en not_active Expired - Lifetime
- 2001-08-13 BR BRPI0113201-6A patent/BR0113201A/pt not_active Application Discontinuation
- 2001-08-13 AU AU8125801A patent/AU8125801A/xx not_active Withdrawn
- 2001-08-13 AT AT01959734T patent/ATE330596T1/de active
- 2001-08-13 DE DE60120990T patent/DE60120990T2/de not_active Expired - Lifetime
- 2001-08-13 ES ES01959734T patent/ES2266229T3/es not_active Expired - Lifetime
- 2001-08-13 TW TW090119751A patent/TWI286933B/zh not_active IP Right Cessation
- 2001-08-13 MX MXPA03001160A patent/MXPA03001160A/es active IP Right Grant
- 2001-08-13 CA CA002418059A patent/CA2418059C/en not_active Expired - Fee Related
- 2001-08-13 WO PCT/US2001/025319 patent/WO2002013805A2/en active IP Right Grant
- 2001-08-13 DK DK01959734T patent/DK1309322T3/da active
- 2001-08-13 PT PT01959734T patent/PT1309322E/pt unknown
- 2001-08-13 US US09/929,704 patent/US6638976B2/en not_active Expired - Lifetime
-
2003
- 2003-11-14 HK HK03108334A patent/HK1057332A1/xx not_active IP Right Cessation
-
2006
- 2006-09-08 CY CY20061101289T patent/CY1106155T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2418059C (en) | 2009-12-22 |
JP2004506010A (ja) | 2004-02-26 |
PT1309322E (pt) | 2006-11-30 |
DE60120990T2 (de) | 2007-03-15 |
AR030346A1 (es) | 2003-08-20 |
TWI286933B (en) | 2007-09-21 |
CA2418059A1 (en) | 2002-02-21 |
AU8125801A (en) | 2002-02-25 |
BR0113201A (pt) | 2006-05-09 |
US6638976B2 (en) | 2003-10-28 |
HK1057332A1 (en) | 2004-04-02 |
ATE330596T1 (de) | 2006-07-15 |
US20020049255A1 (en) | 2002-04-25 |
EP1309322B1 (en) | 2006-06-21 |
WO2002013805A3 (en) | 2002-05-30 |
ES2266229T3 (es) | 2007-03-01 |
DK1309322T3 (da) | 2006-10-23 |
CY1106155T1 (el) | 2011-06-08 |
DE60120990D1 (de) | 2006-08-03 |
WO2002013805A2 (en) | 2002-02-21 |
EP1309322A2 (en) | 2003-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wassermann et al. | Use and safety of a new repetitive transcranial magnetic stimulator | |
WO1998010767A3 (en) | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders | |
WO2003026478A3 (en) | System and method for diagnosing and/or reducing tinnitus | |
WO2002062385A3 (en) | Method to prevent vision loss | |
CA2149924A1 (en) | Use of phenserine to treat cognitive disorders | |
WO2000033814A3 (en) | Method for administering agents to the central nervous system | |
CY1106155T1 (el) | Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους | |
PL370795A1 (en) | Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne | |
EA200300560A1 (ru) | Улучшенный способ лечения | |
WO2001068053A3 (en) | Methods and compositions for treating and preventing posterior segment ophthalmic disorders | |
WO1998026770A3 (en) | The topical use of kappa opioid agonists to treat ocular pain | |
WO2004073607A3 (en) | Use of steroids to treat ocular disorders | |
MXPA03001057A (es) | Metodo para tratar desordenes relacionados con la angiogenesis. | |
PL344574A1 (en) | Cabergoline and pramipexole: new uses and combinations | |
RU94039513A (ru) | Способ лечения отслойки сетчатки, осложненной субретинальным швартообразованием | |
WO2002078681A3 (en) | Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac | |
AU2001267864A1 (en) | Remedial agent for optic nerve disease and the like | |
EP1037622A4 (en) | TAURIN DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS | |
HK1016068A1 (en) | Use of eliprodil for the manufacture of a medicament for the treatment of ischemic disorders of the retina of the optic nerve | |
WO2001043731A3 (en) | Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage | |
WO2003092701A3 (en) | Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders | |
MXPA01011344A (es) | El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. | |
WO2022092907A3 (ko) | 다부위에 적용가능한 플라즈마 치료기 | |
EP1482922A4 (en) | AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS | |
AU1521501A (en) | Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |